Myriad Genetics (MYGN) Tops Q2 EPS by 2c

Myriad Genetics (NASDAQ: MYGN) reported Q2 EPS of $0.26, $0.02 better than the analyst estimate of $0.24. Revenue for the quarter came in at $196.5 million versus the consensus estimate of $189.72 million.

GUIDANCE:

Myriad Genetics sees Q3 2017 EPS of $0.23-$0.25, versus the consensus of $0.25.

For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.

You May Also Be Interested In

• Wolfe Research starts Ferrari at Outperform, sees 'solid upside potential'
• Benchmark Reiterates Buy Rating on Kyivstar Group (KYIV) Following Recent Rally
• Redwood Trust reports record Aspire quarter, launches AI pricing tools